Ctrl Worx Watch List › Company

Zeo ScientifiX, Inc.: material weakness open at least 2,189 days

By , Ctrl Worx™. Built from its own SEC filings. How the Clock works.

Zeo ScientifiX, Inc. reported ineffective internal control over financial reporting because of a material weakness in 7 filings since Feb 8, 2021. It stated one or more material weaknesses in 17 more SEC filings that gave no conclusion on whether that control is effective. The latest was its 10-KT for the period ended Jun 30, 2026.

Ctrl Worx Watch List™ status

On the Clock
6.0 yearsopen since at least Oct 31, 2020
10-KT, Oct 13, 2026latest filing that reports the weakness. Read it on SEC EDGAR
#37 of 1,250on the Clock by time open, tied with 7 other companies that share its start date. See the Clock

Still filing, and no annual report of its own says the weakness is fixed.

Checked against SEC EDGAR: Oct 29, 2026 · Entry #10975

Filings with a weakness24
First in our dataFeb 8, 2021
AuditorWeinberg & Company P.A.

Causes the company named

Not described · 18Segregation of duties · 6Financial close and reporting · 6Accounting expertise and resources · 6ITGC: user access · 6Entity-level and governance · 2

What the latest filing says

Based on that evaluation under this framework, our management concluded that as of June 30, 2026, our internal control over financial reporting was not effective because of the following material weaknesses: [...]

From the controls section of the 10-KT filed Oct 13, 2026. Read the full filing on SEC EDGAR.

Company response: Zeo ScientifiX, Inc. can send a statement or a link to its remediation update to russell@ctrlworx.com. We post it here, unedited and dated.

Filings

FiledFormPeriodControlsCausesFiling
Oct 13, 202610-KTJun 30, 2026Not effectiveNot describedEDGAR
Jun 15, 202610-QApr 30, 2026Material weakness stated, no ICFR conclusionNot describedEDGAR
Mar 17, 202610-QJan 31, 2026Material weakness stated, no ICFR conclusionNot describedEDGAR
Jan 29, 202610-KOct 31, 2025Not effectiveSegregation of duties; Financial close and reporting; Accounting expertise and resources; ITGC: user accessEDGAR
Sep 15, 202510-QJul 31, 2025Material weakness stated, no ICFR conclusionNot describedEDGAR
Jun 16, 202510-QApr 30, 2025Material weakness stated, no ICFR conclusionNot describedEDGAR
Mar 17, 202510-QJan 31, 2025Material weakness stated, no ICFR conclusionNot describedEDGAR
Jan 29, 202510-KOct 31, 2024Not effectiveSegregation of duties; Financial close and reporting; Accounting expertise and resources; ITGC: user accessEDGAR
Sep 16, 202410-QJul 31, 2024Material weakness stated, no ICFR conclusionNot describedEDGAR
Jun 14, 202410-QApr 30, 2024Material weakness stated, no ICFR conclusionNot describedEDGAR
Mar 18, 202410-QJan 31, 2024Material weakness stated, no ICFR conclusionNot describedEDGAR
Jan 29, 202410-KOct 31, 2023Not effectiveSegregation of duties; Financial close and reporting; Accounting expertise and resources; ITGC: user accessEDGAR
Sep 14, 202310-QJul 31, 2023Material weakness stated, no ICFR conclusionNot describedEDGAR
Jun 16, 202310-QApr 30, 2023Material weakness stated, no ICFR conclusionNot describedEDGAR
Mar 17, 202310-QJan 31, 2023Material weakness stated, no ICFR conclusionNot describedEDGAR
Feb 14, 202310-KOct 31, 2022Not effectiveSegregation of duties; Financial close and reporting; Accounting expertise and resources; ITGC: user accessEDGAR
Sep 14, 202210-QJul 31, 2022Material weakness stated, no ICFR conclusionNot describedEDGAR
Jun 14, 202210-QApr 30, 2022Material weakness stated, no ICFR conclusionNot describedEDGAR
Mar 16, 202210-QJan 31, 2022Material weakness stated, no ICFR conclusionNot describedEDGAR
Feb 14, 202210-KOct 31, 2021Not effectiveSegregation of duties; Financial close and reporting; Accounting expertise and resources; ITGC: user access; Entity-level and governanceEDGAR
Sep 14, 202110-QJul 31, 2021Material weakness stated, no ICFR conclusionNot describedEDGAR
Jun 14, 202110-QApr 30, 2021Material weakness stated, no ICFR conclusionNot describedEDGAR
Mar 17, 202110-QJan 31, 2021Material weakness stated, no ICFR conclusionNot describedEDGAR
Feb 8, 202110-KOct 31, 2020Not effectiveSegregation of duties; Financial close and reporting; Accounting expertise and resources; ITGC: user access; Entity-level and governanceEDGAR

Others on the Clock in the same industry

By SEC industry code: 2836, Biological Products, (No Diagnostic Substances), then related codes.

Follow Zeo ScientifiX, Inc. for free

Get an email when Zeo ScientifiX, Inc files a 10-K or 10-Q that reports a material weakness, or says its controls are effective again.

Want the next one the day it's filed?

MW Pro sends an alert the day a company you follow reports a material weakness or says it fixed one. Founding price $990 a year.

Join the MW Pro waitlistLook up any company in Controls Radar™

Watch List Weekly: new material weaknesses, fixes and the longest-running cases, every Monday.

One email to confirm, then one email each Monday. Every email has a one-click unsubscribe. Privacy policy

Based on public SEC filings. Causes are grouped into standard categories by Ctrl Worx. The filings are the authority. Ctrl Worx is not affiliated with Zeo ScientifiX, Inc. or the SEC. Not investment advice. Why you can rely on the Watch List.